

AML Hub | Quarter Two 2020 Update

Tuesday 21 July, 2020

In the second quarter of 2020, the [AML Hub](#) launched its brand-new [website](#). The hub has been redesigned to facilitate navigation, allowing users to filter by disease subtypes, therapeutics, congresses, trials, and expert opinions. A new feature on the website is the podcast channel. Podcasts are available on Apple Podcast, Spotify, and all other major podcast apps to listen to and download. The updated platform further enables the AML Hub to deliver the latest clinical developments. Ultimately, the AML Hub strives to inform real-world clinical practice by providing the latest trial and drug updates, key literature, and congress coverage.

In April the AML Hub covered the [American Association for Cancer Research \(AACR\)](#) Annual Meeting via the social media channels and provided summaries of key sessions. The AML Hub also presented a new editorial theme, '[Use of checkpoint inhibitors in AML therapy](#)', and supported the [AML World Awareness Day](#) with a series of articles on key themes in AML.

In May the AML Hub held a virtual Steering Committee meeting. The AML Hub was also in virtual attendance at the [American Society of Clinical Oncology \(ASCO\) Annual Meeting](#), generating summary articles and video interviews with experts.

Following this in June, we provided coverage of key sessions from the [25th European Hematology Association \(EHA25\) Annual Congress](#) and the second [How to Diagnose and Treat: Acute Leukaemia](#) virtual conference, providing summary articles, podcasts, and expert interviews. The AML Hub also presented a new editorial theme, '[The value of FLT3 targeting in AML](#)'.

Guided by an Executive Steering Committee and Scientific Advisory Board of world-leading experts in acute myeloid leukemia (AML), the AML Hub, in association with the [European LeukemiaNet](#) (ELN), acts to disseminate the latest clinical updates in AML, ensuring healthcare teams are informed and patients with AML have access to the latest drugs and clinical trials.

The AML Hub is a platform brought to you by [Scientific Education Support](#) (SES), who strive to bring increased knowledge and awareness to healthcare professionals via collaborative networks across the globe.

The AML Hub would like to thank its silver supporters, [Amgen](#), [AbbVie](#), [Roche](#), [Genentech](#), [Daiichi-Sankyo](#), and [Novartis](#); bronze supporters, [Astellas](#), [Celgene](#), and [Jazz Pharmaceuticals](#); contributors, [Agiros](#) and [Helsinn](#), for their continued support of the initiative.

For more information on the AML Hub, please visit <https://aml-hub.com/>

For media enquiries or to explore collaboration opportunities, please contact secretariat@scientificeducationsupport.com

Media:

Related Sectors:

Media & Marketing :: Medical & Pharmaceutical ::

Related Keywords:

AML :: Acute Myeloid Leukemia
:: Cancer :: Hematology ::

Scan Me:



Company Contact:

Scientific Education Support

E. [Abbie.Gunn@scientificeducationsupport...](mailto:Abbie.Gunn@scientificeducationsupport.co.uk)

W. [https://www.scientificeducationsuppor...](https://www.scientificeducationsupport.co.uk)

[View Online](#)

Additional Assets:

<https://aml-hub.com/>

Newsroom: Visit our Newsroom for all the latest stories:

<https://www.scientific-education-support.pressat.co.uk>